Antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis is a systemic small-vessel vasculitis comprising three clinical syndromes: granulomatosis with polyangiitis (formerly known as ...

Several new therapies are in development for ANCA vasculitis. Avacopan, an orally administered inhibitor of the complement fragment 5a (C5a) receptor, has been assessed in a phase 3 clinical trial ...

诊断ANCA相关性血管炎需要综合多方面信息，包括临床表现、实验室检查和组织病理学等。其中ANCA的实验室检测是比较关键的一步，要求实验室检验 ...

In this randomized, controlled trial, we assigned patients with ANCA-associated vasculitis in a 1:1 ratio to receive oral avacopan at a dose of 30 mg twice daily or oral prednisone on a tapering ...

Likewise, a positive result may not necessarily be sufficient to diagnose an ANCA-associated vasculitis. MPA is the most common type of ANCA-associated small vessel vasculitis. It is more ...

The reemergence of myeloperoxidase-antineutrophil cytoplasmic antibodies — or MPO-ANCA — can serve as a biomarker to predict relapse in patients who achieved remission in MPO-ANCA–positive ...

This report delivers an in-depth understanding of the ANCA Associated Vasculitis, historical and forecasted epidemiology as well as the ANCA Associated Vasculitis market trends in the United ...

Maintaining remission in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis who have kept their autoantibodies in check after at least 2 years on rituximab therapy has ...

The FDA’s approval for patients with ANCA-associated vasculitis follows results from the phase 3 ADVOCATE trial, in which the drug met its primary endpoints of disease remission at 26 weeks and ...